Karen joined J A Kemp’s Biotechnology and Life Sciences Group in the Oxford office in 2019, having previously worked at another top-tier patent firm in London. Prior to that, Karen completed her PhD in the field of epigenetics, focusing on the role of the non-coding RNA Xist in gene silencing in embryonic stem cells.
What Karen enjoys most about this profession is the constant stimulation from the diversity of the technologies. With a sound knowledge in stem cell biology and gene modification from her PhD days, Karen particularly enjoys dealing with patent applications in these areas. Karen also offers expertise across a wide range of disciplines, including nucleic acid and polypeptide-based therapeutics, antibody therapeutics, vaccines, biomarkers, diagnostics and bioelectronics.
As a patent professional, Karen plays an active role in advising and managing patent portfolios for a wide variety of clients, from small start-up companies to large multinational corporations. In particular, she has experience of managing large, complex portfolios of patent families, including those covering clinical candidates and platform technologies. She has often been involved in “invention mining” and formulating strategies to optimise patent protection tailored to clients’ needs.
Karen has been involved in attacking and defending European patents in opposition and appeal proceedings before the EPO, often involving multiple parties. She also has experience of managing pan European supplementary protection certificate (SPC) application portfolios and advising on issues regarding validity and freedom to operate.
University of Cambridge, Master’s Degree in Natural Sciences (Biochemistry); The Institute of Molecular Pathology (Vienna), PhD in Natural Sciences
European Patent Attorney; UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA); Member of the Institute of Professional Representatives before the European Patent Office (EPI)